Healthcare
Tandem Diabetes Care, Inc.(TNDM)
Live Price
Offline$15.30
-0.65% today
1Y Change
-12.91%
Window
Jun 23, 2025 โ Jun 9, 2026
- Market Cap
- $1.33B
- Revenue Growth
- +7.9%
- EPS Growth
- -106.8%
- Dividend Yield
- 0.0%
Coverage: 242 bars ยท Jun 23, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tandem Diabetes Care, Inc. (TNDM) is a Healthcare stock with a market cap of $1.33B and listed on NASDAQ. The stock last traded around $15.30 and down 12.9% across the available one-year price window (Jun 23, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of +7.9%, EPS growth of -106.8%, a dividend yield of 0.0%. What stands out right now is revenue +7.9%, EPS -106.8%, free cash flow -694.1% with operating margin -18.2% and ROIC -27.8%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TNDM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.9% vs +7.6% peer median
Operating Margin
Below sector median
-18.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.9% and EPS is at -106.8%, with operating margin around -18.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +23.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +7.5% | -0.7% | -7.9% |
2026 Feb 19, 2026 | +80.0% | +32.7% | +39.3% | +33.0% |
2025 Nov 6, 2025 | +0.0% | +22.0% | +31.5% | +56.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNDM
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TNDM Max Drawdown
-54.64%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TNDM and SPY.
Company Overview
Tandem Diabetes Care, Inc.
NASDAQ Global Market
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
- Leadership
- John F. Sheridan
- IPO Date
- Nov 14, 2013
- Employees
- 2.6k
- Street Address
- 11075 Roselle Street
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 366 6900
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.3
- Price/Book
- 8.5
Growth
- Revenue
- +7.9%
- EPS
- -106.8%
- Free Cash Flow
- -694.1%
Profitability
- Gross Margin
- 53.8%
- Operating Margin
- -18.2%
- Net Margin
- -20.2%
- ROE
- -142.0%
- ROIC
- -27.8%
Balance Sheet
- Debt/Equity
- 3.64
- Current Ratio
- 2.55
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.